Skip to main content

Drug Interactions between cisatracurium and methoxyflurane

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

methoxyflurane cisatracurium

Applies to: methoxyflurane and cisatracurium

ADJUST DOSE: Inhalation anesthetics may potentiate the effects of nondepolarizing muscle relaxants. Long-acting muscle relaxants such as pancuronium and d-tubocurarine are more affected than other agents.

MANAGEMENT: The muscle relaxant dosage may need to be reduced when inhalation anesthetics are used, especially during longer procedures. In general, inhalation anesthetics should be administered only by health care providers specially trained in the use of these agents and in the care of anesthetized patients.

References (9)
  1. Kronenfeld MA, Thomas SJ, Turndorf H (1986) "Recurrence of neuromuscular blockade after reversal of vecuronium in a patient receiving polymyxin/amikacin sternal irrigation." Anesthesiology, 65, p. 93-4
  2. Miller RD, Eger EI, Way WL, Stevens WC, Dolan WM (1971) "Comparative neuromuscular effects of forane and halothane alone and in combination with d-tubocurarine in man." Anesthesiology, 35, p. 38-42
  3. Duncalf D, Nagashima H, Hollinger I, Badola RP, Kaplan R, Foldes FF (1981) "Relaxation with ORG-NC45 during enflurane anesthesia." Anesthesiology, 55, a203
  4. Ramsey FM, White PA, Stullken EH, Allen LL, Roy RC (1982) "Enflurane potentiation of neuromuscular blockade by atracurium." Anesthesiology, 57, a255
  5. Swen J, Rashkovsky OM, Ket JM, Koot HW, Hermans J, Agoston S (1989) "Interaction between nondepolarizing neuromuscular blocking agents and inhalational anesthetics." Anesth Analg, 69, p. 752-5
  6. Withington DE, Donati F, Bevan DR, Varin F (1991) "Potentiation of atracurium neuromuscular blockade by enflurane: time-course of effect." Anesth Analg, 72, p. 469-73
  7. (2001) "Product Information. Ultane (sevoflurane)." Abbott Pharmaceutical
  8. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  9. Cerner Multum, Inc. "Australian Product Information."

Drug and food interactions

Moderate

methoxyflurane food

Applies to: methoxyflurane

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents. Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References (5)
  1. Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  4. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  5. (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer